Inventor · disambiguated record
Bradley Keller
Also filed as: KELLER BRADLEY T
11 granted patents·18 pending applications·287 citations·filing 1998–2019
92Inventor score
Top patents by PatentIndex Score
29 records- 0196US6943189B2Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitorsSEARLE & CO·Filed 2003·Granted Sep 13, 2005·78 cites·40 claims
- 0291US6420417B1Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitorsSEARLE & CO·Filed 2000·Granted Jul 16, 2002·37 cites·50 claims
- 0388US8710191B2Antibodies to CCR2GLADUE RONALD P·Filed 2009·Granted Apr 29, 2014·21 cites·11 claims
- 0487US6642268B2Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitorsSEARLE & CO·Filed 2002·Granted Nov 4, 2003·22 cites·18 claims
- 0578US6562860B1Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indicationsSEARLE & CO·Filed 1999·Granted May 13, 2003·39 cites·11 claims
- 0677US6458851B1Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indicationsSEARLE LLC·Filed 1999·Granted Oct 1, 2002·35 cites·8 claims
- 0775US11389456B2Compounds and methods for treating oxalate-related diseasesOXALURX INC·Filed 2019·Granted Jul 19, 2022·1 cites·20 claims
- 0872US6268392B1Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitorsSEARLE & CO·Filed 1998·Granted Jul 31, 2001·37 cites·49 claims
- 0970US9238691B2Nucleic acids encoding antibodies to CCR2PFIZER·Filed 2014·Granted Jan 19, 2016·1 cites·31 claims
- 1068US2007203246A1Combinations of Cholesterol Ester Transfer Protein Inhibitors and HMG COA Reductase Inhibitors for Cardiovascular IndicationsPFIZER·Filed 2007·Application pending·0 cites
- 1164US6462091B1Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indicationsSEARLE & CO·Filed 1999·Granted Oct 8, 2002·15 cites·11 claims
- 1259US2004110761A1Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disordersSEARLE LLC·Filed 2003·Application pending·0 cites
- 1359US2003166712A1Combinations of cholesteryl ester transfer protein inhibitors and HMG CoA reductase inhibitors for cardiovascular indicationsSEARLE & CO·Filed 2002·Application pending·0 cites
- 1452US2002061888A1Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disordersFiled 2001·Application pending·0 cites
- 1549US2004048846A1Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indicationsSEARLE LLC·Filed 2003·Application pending·0 cites
- 1648US2004029845A1Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indicationsSEARLE & CO·Filed 2003·Application pending·0 cites
- 1747US2003203892A1Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indicationsSEARLE LLC·Filed 2002·Application pending·0 cites
- 1846US2003232834A1Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disordersFiled 2001·Application pending·0 cites
- 1945US2003199482A1Therapeutic combinations for cardiovascular and inflammatory indicationsPHARMACIA CORP·Filed 2002·Application pending·0 cites
- 2044US2006003975A1Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitorPHARMACIA CORP·Filed 2005·Application pending·0 cites
- 2144US2004186154A1Therapeutic combinations for cardiovascular and inflammatory indicationsFiled 2002·Application pending·0 cites
- 2243US2014271734A1Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux diseaseLUMENA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2343US2014275090A1Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel diseaseLUMENA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2442US2003125316A1Combinations of lleal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indicationsSEARLE LLC·Filed 2002·Application pending·0 cites
- 2540US2004067918A1Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivativeFiled 2003·Application pending·0 cites
- 2640US2003219401A1Combination of an aldosterone receptor antagonist and a bile acid sequestering agentFiled 2003·Application pending·0 cites
- 2739US2004058908A1Combinations for cardiovascular indicationsSEARLE LLC·Filed 2002·Application pending·0 cites
- 2839US2003149010A1Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitorFiled 2002·Application pending·0 cites
- 2934US6638969B1Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indicationsSEARLE LLC·Filed 1999·Granted Oct 28, 2003·1 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Bradley Keller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →